Patent offices

IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals

Friday, March 27, 2020 - 12:30am

IGC filed this application for its IGC-504 formulation (#15/751,901) on August 11, 2016.

Key Points: 
  • IGC filed this application for its IGC-504 formulation (#15/751,901) on August 11, 2016.
  • A public copy of the patent is available on the USPTO website.
  • A patent for an invention is the grant of a property right to the inventor, issued by the USPTO.
  • The company is based in Maryland, U.S.A. Our website: www.igcinc.us .Twitter @IGCIR
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005803/en/

SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039

Wednesday, March 18, 2020 - 10:30am

The 087 patent is a composition of matter patent that covers the polymorphic form of nirogacestat that is currently in clinical development.

Key Points: 
  • The 087 patent is a composition of matter patent that covers the polymorphic form of nirogacestat that is currently in clinical development.
  • SpringWorks has exclusive rights to the 087 patent pursuant to an existing worldwide license with Pfizer.
  • We are very pleased that the USPTO has issued this patent, which builds upon our existing intellectual property portfolio and extends patent protection for nirogacestat to 2039, said Saqib Islam, Chief Executive Officer of SpringWorks.
  • In addition, SpringWorks is seeking to advance nirogacestat as a cornerstone of B-cell maturation antigen (BCMA) combination therapy in multiple myeloma.

AKHAN Semiconductor Announces Major European Patent

Wednesday, February 26, 2020 - 12:56pm

AKHAN Semiconductor , a technology company specializing in the fabrication and application of lab-grown, electronic-grade diamonds, announced today that it has been issued a patent by the European Patent Office (EPO).

Key Points: 
  • AKHAN Semiconductor , a technology company specializing in the fabrication and application of lab-grown, electronic-grade diamonds, announced today that it has been issued a patent by the European Patent Office (EPO).
  • The patent covers AKHANs next-generation N-type diamond semiconductor system and diamond-based multilayer antireflective coating systems, key components in military & aerospace sensor and detector applications, amongst other use cases.
  • 2737112, is another key addition to AKHANs breakthrough Miraj Diamond intellectual property portfolio, and the Companys first European-issued patent.
  • Over the past few months, AKHAN has been issued a number of patents from around the world, and this latest from the European Union is further proof that were world leaders in producing diamond technology for semiconductor application, said Adam Khan, Founder and CEO of AKHAN Semiconductor.

United States Patent & Trademark Office (USPTO) hosting a job fair in Atlanta, GA on February 21st - February 22nd, where USPTO is hiring hundreds of new examiners in 2020

Saturday, February 15, 2020 - 4:45pm

The USPTO is hiring 100s of engineers to examine America's patents in 2020!

Key Points: 
  • The USPTO is hiring 100s of engineers to examine America's patents in 2020!
  • Even more positions will be opening up in the agency's Rocky Mountain regional office in Denver later in the year.
  • Patent examination is a mission-critical component of the intellectual property ecosystem and the agency's efforts to safeguard American ingenuity.
  • Our examiners work closely with entrepreneurs to process their patent applications and determine whether or not a patent can be granted.

ERS Genomics Provides Comment on Affirmation of Key CRISPR-Cas9 Patent Involved in European Opposition Proceedings

Monday, February 10, 2020 - 2:55pm

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier, announced today that the European Patent Office (EPO) has rejected arguments filed in opposition to European patent No.

Key Points: 
  • ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier, announced today that the European Patent Office (EPO) has rejected arguments filed in opposition to European patent No.
  • Dr. Emmanuelle Charpentier, co-inventor of the patent and founder of ERS Genomics, commented: "It is gratifying to have the European patent office confirm the novelty and inventiveness of this discovery.
  • Eric Rhodes, Chief Executive Officer, ERS Genomics, said: The outcome of the opposition hearing reinforces the broad and fundamental nature of this patent.
  • ERS Genomics Limited was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by its founder Dr. Emmanuelle Charpentier.

No Borders, Inc. (Ticker: NBDR) Announces Blockchain Patent Filing With the USPTO

Tuesday, February 4, 2020 - 2:19pm

This provisional patent, registered as Application Serial #62969531 with the USPTO on Feb. 3, 2020, now allows the Companys CBD LabChain platform to operate with Patent Pending identifiers and messaging.

Key Points: 
  • This provisional patent, registered as Application Serial #62969531 with the USPTO on Feb. 3, 2020, now allows the Companys CBD LabChain platform to operate with Patent Pending identifiers and messaging.
  • The Provisional Patent for CBD LabChain was filed with the title:
    No Borders, Inc. CEO Joseph Snyder stated, It has been a long road to get to this day and I am stoked to share our first patent filing with the world!
  • This filing marks a milestone for our Company and our amazing shareholders.
  • No Borders Naturals now certifies 100% ofits products and their efficacy via the Companys breakthrough CBD LabChain Certification Platform.

It's Official: Canon Places 3rd in IFI CLAIMS 2019 U.S. Patent Rankings

Wednesday, January 15, 2020 - 6:48pm

With this year's ranking, Canon has become the only company in the world to have ranked in the top five for number of patents granted for 34 consecutive years.

Key Points: 
  • With this year's ranking, Canon has become the only company in the world to have ranked in the top five for number of patents granted for 34 consecutive years.
  • Additionally, Canon has once again ranked first in patents among Japanese companies for the 15th consecutive year.
  • Canon U.S.A., Inc., is a leading provider of consumer, business-to-business, and industrial digital imaging solutions to the United States and to Latin America and the Caribbean markets.
  • Based on weekly patent counts issued by United States Patent and Trademark Office.

Auris Medical Announces Notice of Allowance for European Patent Application

Friday, January 10, 2020 - 1:30pm

Hamilton, Bermuda, January 10, 2020 Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the European Patent Office (EPO) has issued a notice of Intention to Grant for its patent application entitled Treatment of Tinnitus Through Modulation of Chloride Co-Transporter NKCC1 in the Auditory System (European Patent Application 11 894 529.3).

Key Points: 
  • Hamilton, Bermuda, January 10, 2020 Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the European Patent Office (EPO) has issued a notice of Intention to Grant for its patent application entitled Treatment of Tinnitus Through Modulation of Chloride Co-Transporter NKCC1 in the Auditory System (European Patent Application 11 894 529.3).
  • The communication from the EPO concludes substantive examination of the patent application, which is now expected to issue as a patent once the issue fees are paid and the patent office concludes its respective administrative procedures.
  • A corresponding patent application is currently pending before the US Patent and Trademark Office (USPTO) and was already granted in Japan.
  • Auris Medical is a biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders.

University of California's Foundational CRISPR-Cas9 Patent Portfolio Reaches 20 Total U.S. Patents

Tuesday, December 31, 2019 - 5:30am

BERKELEY, Calif., Dec. 31, 2019 /PRNewswire/ -- Today, the U.S. Patent and Trademark Office (USPTO) granted a new CRISPR-Cas9 gene-editing patent (U.S. Patent 10,519,467) to the University of California (UC), University of Vienna, and Dr. Emmanuelle Charpentier, marking the 20th patent in the university's CRISPR-Cas9 portfolio.

Key Points: 
  • BERKELEY, Calif., Dec. 31, 2019 /PRNewswire/ -- Today, the U.S. Patent and Trademark Office (USPTO) granted a new CRISPR-Cas9 gene-editing patent (U.S. Patent 10,519,467) to the University of California (UC), University of Vienna, and Dr. Emmanuelle Charpentier, marking the 20th patent in the university's CRISPR-Cas9 portfolio.
  • In 2019, UC's intellectual property protection for the technology has grown exponentially to include 18 new U.S. patents.
  • Looking ahead to 2020, UC has received notices of allowance from the USPTO for five additional patent applications, further bolstering its expansive portfolio.
  • International patent offices have also recognized the pioneering innovations of the Doudna-Charpentier team, in addition to the 20 patents granted in the U.S. so far.

IP Litigation Duo Rejoins Bracewell in Austin as Texas Becomes Increasingly Popular Jurisdiction for Patent Disputes

Monday, December 9, 2019 - 3:00pm

"They are exceptional litigators who are highly regarded in the IP and Texas legal communities, and their addition will strengthen our firm-wide IP litigation practice."

Key Points: 
  • "They are exceptional litigators who are highly regarded in the IP and Texas legal communities, and their addition will strengthen our firm-wide IP litigation practice."
  • Chibib has a broad IP litigation practice that includes representing companies in the semiconductor, telecommunications, electronics and software fields.
  • Chibib also has an active post-grant practice before the US Patent and Trademark Office's (USPTO) Patent Trial and Appeal Board.
  • This includes patent litigation, trademark and trade secret disputes, as well as disputes involving breach of contract, fraud, unfair competition and breach of fiduciary duty.